Vireo Growth (VREOF) Restructuring Costs (2020 - 2026)
Vireo Growth (VREOF) posted Restructuring Costs of $7.2 million for Q1 2026, down 46.95% sequentially from $13.6 million in Q4 2025, and up 620.0% YoY from $1.0 million in Q1 2025.
Vireo Growth (VREOF) Restructuring Costs (2020 - 2026) Analysis & Trends
Vireo Growth has reported Restructuring Costs for 7 years, with the latest figure at $7.2 million in Q1 2026.
- Quarterly Restructuring Costs rose 620.0% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.9 million (up 495.5% YoY) and the FY2025 annual result came in at $20.4 million, up 351.83% from the prior year.
- Restructuring Costs slipped to $7.2 million in Q1 2026 per VREOF's latest filing, from $13.6 million in the prior quarter.
- Over five years, Restructuring Costs peaked at $13.6 million in Q4 2025 and troughed at $182602.0 in Q4 2024.
- A 5-year average of $2.5 million and a median of $1.6 million in 2024 frame the typical range for Restructuring Costs.
- The sharpest annual moves came in 2024 and 2025: Restructuring Costs tumbled 79.7% in 2024, then jumped 7332.89% in 2025.
- Over 5 years, Restructuring Costs stood at $1.5 million in 2022, then tumbled by 40.58% to $899519.0 in 2023, then sank by 79.7% to $182602.0 in 2024, then surged by 7332.89% to $13.6 million in 2025, then slumped by 46.95% to $7.2 million in 2026.
- According to Business Quant data, Restructuring Costs over the past three periods registered $7.2 million, $13.6 million, and $803724.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | Vireo Growth | 482.88 Mn | 340.58 Mn | 95.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.20 Mn |
| Dec 31, 2025 | 13.57 Mn |
| Sep 30, 2025 | 803,724.00 |
| Jun 30, 2025 | 3.34 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 182,602.00 |
| Sep 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 1.43 Mn |
| Mar 31, 2024 | 1.32 Mn |
| Dec 31, 2023 | 899,519.00 |
| Sep 30, 2023 | 1.40 Mn |
| Jun 30, 2023 | 1.59 Mn |
| Mar 31, 2023 | 1.61 Mn |
| Dec 31, 2022 | 1.51 Mn |
| Sep 30, 2022 | 1.84 Mn |
| Jun 30, 2022 | 2.10 Mn |
| Mar 31, 2022 | 1.95 Mn |
| Dec 31, 2021 | 1.75 Mn |
| Sep 30, 2021 | 2.06 Mn |
| Jun 30, 2021 | 2.34 Mn |